Purpose: This study attempted to determine the prognostic value for survival of various pretreatment characteristics in patients with nonresectable non-small-cell lung cancer in the context of more than 10 years of experience of a European Cooperative Group, Patients and Methods: We included in the analysis all eligible patients (N = 1,052) with advanced non-small-cell lung cancer registered onto one of seven trials conducted by the European Lung Cancer Working party (ELCWP) during one decode, The patients were treated by chemotherapy regimens based on platinum derivatives. We prospectively collected 23 variables and analyzed them by univariate and multivariate methods. Results: The global estimated median survival time was 29 weeks, with a...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
The FLEX study demonstrated that the addition of cetuximab to chemotherapy significantly improved ov...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Objectives: In patients with advanced incurable lung cancer deciding as to the most appropriate trea...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
The FLEX study demonstrated that the addition of cetuximab to chemotherapy significantly improved ov...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Purpose: Knowledge of prognostic factors for advanced non-small-cell lung cancer (NSCLC) patients el...
Objectives: In patients with advanced incurable lung cancer deciding as to the most appropriate trea...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...
The FLEX study demonstrated that the addition of cetuximab to chemotherapy significantly improved ov...
Purpose: Although patients with stage III non-small cell lung cancer (NSCLC) are homogeneous accordi...